Form 4: CRISPR Therapeutics GC Sells Shares for Tax

CRISPR Therapeutics General Counsel James R. Kasinger sold 3,450 common shares to cover tax obligations following the vesting of restricted stock units.

Summary

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, acquired 6,875 common shares on March 14, 2026, due to the vesting of restricted stock units.
• Following this acquisition, Kasinger disposed of 3,450 common shares on March 16, 2026, at a price of $48.26 per share.
• This sale was a mandatory transaction to cover tax withholding obligations related to the RSU vesting and was not a discretionary trade by the reporting person.
• After these transactions, Kasinger beneficially owns 91,240 common shares directly.
• The restricted stock unit award, granted on March 14, 2025, for 27,500 common shares, vests in four equal annual installments, with the first quarter vesting on March 14, 2026.
• Remaining shares from the RSU vesting are subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the share disposition was non-discretionary and for tax purposes, not indicative of a change in insider sentiment or company prospects.

Positives

• The vesting of 6,875 restricted stock units indicates continued compensation and retention of a key executive.

Future Outlook

The remaining Restricted Stock Units are scheduled to vest in three equal annual installments on March 14, 2027, March 14, 2028, and March 14, 2029.

Industry Context

StockSavvy.ai notes that routine insider transactions, particularly those mandated for tax purposes following RSU vesting, are common across the biotechnology sector and generally do not signal a change in company fundamentals or insider sentiment.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale was non-discretionary and relatively small compared to total outstanding shares.
• Employees: The RSU vesting and tax-related sale illustrate standard executive compensation practices.

Next Steps

• Remaining Restricted Stock Units will vest in three equal annual installments on March 14, 2027, March 14, 2028, and March 14, 2029.

Key Dates

Recommendation

The transaction is a routine, non-discretionary sale by an insider to cover tax obligations associated with RSU vesting. It does not reflect a change in the insider's view of the company's prospects or fundamental performance, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, James R. Kasinger, General Counsel, Biotechnology, Gene Editing